Greenphire, a King of Prussia, Pa.-based provider of clinical research payment technology, has brought on global private equity firm The Riverside Company as a new growth investor. The partnership and investment is designed to further enable Greenphire to expand operational infrastructure to support its rapidly expanding global client base, expand its product suite and accelerate the company’s commercialization efforts. 

“Greenphire has experienced exponential growth each year since its inception. The management team has worked hard to grow while scaling its operations to ensure continued quality,” said Dr. Neil Rotherham, chairman of Greenphire.

Greenphire’s eClinicalGPS and ClinCard products enable sponsors, CROs and research sites to utilize a web-based technology solution to improve patient and site payment processes, drive strategic value through analytics, improve patient retention and compliance and reduce overall costs in the clinical trial payment process.